Inhibikase Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Net Loss Per Share

Net Loss Per Share

9 Months Ended

Sep. 30, 2023

Earnings Per Share [Abstract]

Net Loss Per Share

11.

Net Loss Per Share

The following table presents the calculation of basic and diluted net loss per share applicable to common stockholders:


	Three Months Ended September 30,						Nine Months Ended September 30,
	2023			2022			2023			2022
Numerator:
Net loss	$	(4,595,199	)	$	(4,494,563	)	$	(14,850,943	)	$	(13,775,103	)
Denominator:
Weighted-average number of common shares outstanding – basic and diluted		5,342,337			4,224,294			5,060,447			4,223,099
Net loss per share applicable to common stockholders – basic and diluted	$	(0.86	)	$	(1.06	)	$	(2.93	)	$	(3.26	)

The following shares were excluded from the calculation of diluted net loss per share applicable to common stockholders, prior to the application of the treasury stock method, because their effect would have been anti-dilutive for the periods presented:


	Nine Months Ended September 30,
	2023		2022
Options to purchase shares of stock		835,913		671,347
Warrants to purchase shares of stock		3,080,090		260,319
Total		3,916,003		931,666